JSOM - Full Issues Home Articles Publication Advertisers TCCC Prof Dev Partners Newsletters Subscriptions Staff Get your NATO Supplement Digital or Tablet formats available Find us on the Social Media sites: The OFFICIAL Journal of the Special Operations Medical Association Sign up here for your FREE 3-day digital trial Shared Science Full JSOM Issues Med Quiz Full Issues Advanced Tactical Paramedic Protocols Handbook Training Supplement MedQuiz Winter 2010 Winter 2009 Spring 2009 Winter 2008 Spring 2008 Summer 2008 Fall 2008 Winter 2007 Spring 2007 Summer 2007 Fall 2007 The JSOM is published by Breakaway Media, LLC, is a female veteran-owned business Registered with Central Contracting Office of the Department of Defense DUNS #070397122 / Cage #6F0Z6 Primary SIC Code - 2721 All rights reserved. Journal of Special Operations Medicine
Artificial Vision for the Blind - Glasses That Give Sight To The Blind WHO estimates that 180 million people worldwide suffer from visual impairment, and of those individuals, between 40 and 45 million are blind. With a growing population, these figures will double by 2020. More than seven million people become blind every year, with 90% of those cases occurring in developing countries. Artificial Vision for the Blind has created a system that helps restore lost vision in those who are blind. Generated $100,000 USD in revenue.Awards: Universidad Nacional Autónoma de México (UNAM), Consejo Nacional de Ciencia y Tecnología (CONACYT), Instituto Nacional de Ciencia y Tecnología del Distrito Federal (ICYTDF), Secretaría Educación Pública (SEP), and Instituto Mexicano de la Juventud: Innovación Tecnológica (IMJ).
PAEA Evolving Technologies - Medical Solutions For The Developing World Millions of patients in developing countries are deprived of common procedures relating to respiratory, gynecological, gastrointestinal, etc. issues due to the high cost of equipment and training related to endoscopy treatments. Using bottom-up innovation techniques, Evolving Technologies created an endoscopy system for the needs of developing markets for less than 4% of the market price. Their main product today is a light, portable endoscopy system for women’s health, the EvoCam. They also have the EvoLight, a light, portable, LED-based medical light-source powered by a USB. MIT $100K track finalist 2011.Hub Ventures finalist 2011.Granted MIT IDI Technology Dissemination Fellowship 2011.Joint project with IDEO.ORG on EvoCam design and business model 2011.
HSL Recruitment - Employment Vacancies Rural Hospital Medicine – Senior Medical Officer position Dunstan Hospital Dunstan Hospital is a 32 bed acute care rural hospital located in Clyde, Central Otago. We have a part time position available within the senior clinical team providing acute care and rural hospital inpatient care at Dunstan. Clinical services at Dunstan Hospital include: Acute 24 hour inpatient care and emergency services, 3 bed high dependency unit, on-site radiology (incl. Applications should be forwarded inconfidence to the Clinical Director, Dunstan Hospital, PO Box 30, Clyde 9341. or emailed to: rob.visser@cohealth.co.nz
Solar Ear - Solar Powered Hearing Aids There are almost 600 million hearing impaired people in the world, with two thirds of those individuals living in developing countries. The availability and affordability of hearing aids and batteries impede solutions to hearing loss. Solar Ear developed the first rechargeable hearing aid battery, which lasts for 2-3 years and can be used in 80% of hearing aids on the market today. Products are sold in over 40 countries.Manufacturing facilities in 2 countries.Generated over USD$1,000,000 in revenue.In Botswana and Brazil, the project was directly responsible for the employment of 35 young adults with disabilities into other organizations, not including the 40 employed with Solar Ear.
Home - Healthy Christchurch UP Magazine Œil bionique : Le Ministère canadien de la Santé autorise Argus II, le système de prothèse épirétinienne de Second Sight, pour le traitement de la dégénérescence rétinienne périphérique Argus II est le premier œil bionique autorisé au Canada pour le traitement de la cécité due à la dégénérescence rétinienne périphérique. Déjà autorisée à la vente sur le marché européen depuis 2011, la prothèse rétinienne Argus II commercialisée par la société californienne Second Sight vient d'obtenir l'autorisation du Ministère canadien de la Santé (Health Canada) pour l’utilisation de la prothèse Argus II pour le traitement de patients atteints de dégénérescence rétinienne périphérique sévère à majeure.Des prothèses visuelles implantables permettant de restituer une partie de la fonction visuelle de patients non-voyants. Dejà de nombreux patients dans le monde Le système Argus II de Second Sight a obtenu le marquage CE en Europe en 2011 et l’autorisation de la FDA américaine en 2013.
American Academy on Communication in Healthcare > Smith's Patient-Centered Interviewing Improving Efficiency, Effectiveness, Patient Satisfaction and Health Outcomes through Patient-Centered Interviewing AACH faculty offer consultative services and a workshop at your location to guide participants through the patient-centered interview method described in the book and videos. Click the flier to learn more about the workshop or contact us to discuss consultation for developing your customized curriculum.
Apple Announces iLens, The ‘Smart Contact Lenses’ Apple just announced the launch of the iLens, a smart contact lens that works like the Google Glass but “better” according to James Milton, an Apple rep. The iLens costs $299 for 64GB and $499 for 124GB, and Apple hopes it will compliment the iWatch and iPhone. The iLens comes with a clear earpiece and is activated by a series of the user’s blinks. “Sure, you may look like you’re having a stroke when you wear an iLens, but still look less dorky than wearing Google Glass,” said the designer, Parker Johnson. “It’s applied just like a contact lens, so a licensed optometrist will have to fit users for the iLens. The iLens works just like an iPhone. “Cellphones have become a huge social faux pas. A new series of apps specifically designed for the iLens will be released too. “Have you ever wanted to know what it would be like to sleep with Kate Upton or Ryan Gosling is like? “The best part about the iLens may be the camera. The iLens will be released May 2015 with the iLens Air model late 2015.
Physician associate (physician assistant) What: A clinical role under the supervision of a doctor who is responsible for the care of patients and tailors the physician associate’s scope of practice according to their skills and the patient profile. The role was developed in the United States in the 1960s to address workforce shortages. The Netherlands, Canada and the UK have recently adopted the role. Australia has also run trials, and as a result has started a training programme at a Queensland university. Aims: For physician associates to serve in a complementary role, working alongside doctors, nurses and others. Where: After an initial demonstration where two US-trained physician associates worked at Middlemore Hospital, a second phase, again with physician associates from the US, is underway in Tokoroa, Hamilton and Gore. New Zealand faces significant workforce challenges in rural and semi-rural areas, and testing the physician associate role in such locations has already contributed some useful lessons.
Seintinelles - Contre le cancer, tous volontaires PA Forum CMC hosted a forum in March to discuss extended nursing roles and physician assistants and the how these roles work in the multidisciplinary team. An official position statement has since been developed. CMC Position Statement Since the forum in March, CMC has developed a position statement on advanced nursing scopes and physician assistant developments: Click here to read the statement. Forum on Physician Assistants and Advanced Nursing Roles - 8 March 2013 The forum was overall, a very informative excercise with presentations from different sector representatives including doctors, clinical nurse specialists, a physician assistant, a nurse practitioner and from other sector stakeholders such as the Medical Council, the New Zealand Nursing Organisation, Health Workforce New Zealand and the Ministry of Health. Guest presentations are available to CMC Members and a summary of the meeting can be found here. ← Back to News
Diabète de type 1 : résultats prometteurs d’un prototype de "pancréas bionique bihormonal" Le Dr Edward Damiano et ses collaborateurs de l’université de Boston ont testé ce qu’ils appellent eux-mêmes un "pancréas bionique bihormonal", nouveau prototype de pancréas artificiel composé de 3 boîtiers pilotés par un smartphone. Leur étude, publiée dans le New England Journal of Medicine, a permis de comparer son efficacité à celle de la pompe à insuline seule auprès de 52 patients diabétiques de type 1. Les résultats, très préliminaires mais prometteurs, permettent d’espérer une optimisation du contrôle de la glycémie et de l'autonomie des patients avec ce type de dispositif, qui automatise le contrôle glycémique et la délivrance d'insuline, mais aussi la prise en charge des hypoglycémies. "Pancréas bionique" composé d’un IPhone, d’une pompe à insuline et d’une pompe à glucagon. Le dispositif de mesure continue de la glycémie n'est pas représenté (© Université de Boston).